Search Results
Keywords: dronabinol
Will rescheduling reroute the future of interstate commerce for cannabis?
Some cannabis executives are hopeful that if the federal government moves marijuana from Schedule 1 to 3 of the Controlled Substances Act, then transporting MJ products across state lines will be allowed.
German cannabis imports growing as Canada’s leading share wanes
Germany imported a record amount of cannabis for medical sales and scientific use in the first half of this year, putting the European Union’s biggest market on pace to match or possibly surpass 2021’s total.
How will inflation impact cannabis retail + two deals that illustrate industry change
While wholesale cannabis prices have been going up – sometimes as much as 30%, according to a recent MJBizDaily story – retail prices for the consumer haven’t been keeping pace.
Insurance-covered medical cannabis reimbursements decline again in Germany
Public health insurance reimbursements for cannabis in Germany have fallen for the second straight quarter.
As competition grows in German medical cannabis flower market, sales strategy becomes key
The growing number of medical cannabis brands and products available to patients in Germany indicates that companies wanting to enter and succeed in that market need to think beyond simply offering a consistent supply of products.
Synthetic cannabinoids linked to increased hospitalizations and deaths in older adults with COPD
A study out of St. Michael’s Hospital in Toronto has found prescription synthetic cannabinoids are linked to a 64% increase in death in older patients with chronic obstructive pulmonary disease (COPD). These oral drugs—nabilone and dronabinol—have a chemical structure similar to THC and are often prescribed to treat symptoms associated with COPD, including pain, sleep difficulties and breathlessness.
Spain still won’t allow local cannabis market, even as exports are occurring
Spain has several medical cannabis licensed producers, and at least one already exports flower to countries such as Germany.
Insurance-covered medical cannabis falls for the first time in Germany
Insurance reimbursements for cannabis in Germany dropped for the first time – on a quarterly basis – since the current medical program started in early 2017, according to new data for the quarter ended June 30, 2020.
Global Retreat: Canadian cannabis firms pull back global aspirations
Back in the early days of Canada’s regulated adult-use cannabis industry, some of the country’s biggest publicly traded marijuana producers discovered that investors rewarded international ambitions.
Insurance-covered reimbursements for medical cannabis sets record in Germany
Insurance reimbursements for medical cannabis in Germany continue to reach fresh quarterly records, according to new data for the January-March period.
